Medication Therapy Management, Pharmacogenomics
Conditions
Keywords
Pharmacogenomics, Medication Therapy Management
Brief summary
The aim of this study is to evaluate and describe the feasibility of implementing a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.
Detailed description
To determine if a pharmacogenomics (PGx) service can become a component of everyday practice, feasibility assessments are needed. While some researchers have begun to assess the feasibility of implementing PGx into pharmacy practice in community-based practice settings, none that we are aware have assessed such feasibility for the Program of All-inclusive Care for the Elderly (PACE). The primary objective of this feasibility study is to evaluate the processes that were involved in implementing a pharmacist-led PGx service for PACE and to describe process-related challenges and solutions associated with implementation. Secondary objectives include: describe pharmacists' roles in the implementation process; report aggregate PGx test results, including genetic variants and drug-gene interactions; and describe pharmacists' recommendations to personalize drug regimens for PACE participants and prescribers' acceptance of these recommendations.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Participant enrolled in PACE contractually receiving pharmacy services from Tabula Rasa Healthcare (CareKinesis Pharmacy) during the project time period (May 2014 through June 2016); and * PACE prescriber ordered a pharmacogenomics test for the participant as part of clinical care; and, * PACE participant consented to a pharmacogenomics test; and, * CareKinesis pharmacist provided a consultation directly to PACE prescriber based on the participant's pharmacogenomics test results.
Exclusion criteria
* Participant dis-enrolled from PACE prior to receiving pharmacogenomics test results and/or prior to CareKinesis pharmacist providing consultative services; or, * Participant did not complete the pharmacogenomics test.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Implementation Primary | 24 months | Qualitative description of process-related challenges and successes as assessed by observation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Implementation Secondary | 24 months | Qualitative description of pharmacists' roles as assessed by observation |
| Pharmacogenomic Testing | 24 months | Quantitative description of pharmacogenomic testing results as assessed by analysis of genotype and phenotype |
| Pharmacist Recommendations | 24 months | Qualitative and quantitative descriptions of pharmacists' pharmacogenomic-based recommendations to prescribers as assessed by evaluation of consultations |
| Prescriber Acceptances | 24 months | Qualitative and quantitative descriptions of prescribers' acceptances of pharmacists' recommendations as assessed by responses and post-consultation drug profile reviews |